WASHINGTON (Reuters) - Novartis AG has agreed to sell its nicotine patch, Habitrol, in order to win U.S. antitrust approval for a consumer healthcare joint venture with Britain's GlaxoSmithKline, the U.S. Federal Trade Commission said on Wednesday. Novartis and GlaxoSmithKline had previously announced that they were creating the venture, and that Glaxo would buy Novartis' vaccines business, excluding flu vaccines. Novartis would buy Glaxo's oncology drugs portfolio, the companies said in April. ...
via Health News Headlines - Yahoo News http://ift.tt/1uImLUJ
No comments:
Post a Comment